Meeting Overview - The second supervisory board meeting of Jiangsu Huasheng Lithium Battery Materials Co., Ltd. was held on August 26, 2025, combining on-site and remote participation [1] - The meeting was chaired by the chairman of the supervisory board, Zhou Chao, and all resolutions made were deemed legal and effective according to relevant laws and regulations [1] Financial Reporting - The supervisory board approved the company's 2025 semi-annual report, confirming that the preparation and review processes complied with relevant laws and internal regulations, accurately reflecting the company's financial status and operational results for the first half of 2025 [1][2] - The supervisory board ensured that there were no violations of confidentiality during the report preparation process and that the report contained no false statements or significant omissions [1] Fund Management - The supervisory board confirmed that the management of raised funds for the first half of 2025 complied with relevant laws and regulations, with funds stored in dedicated accounts and used for specified purposes [2] - The company disclosed the actual use of raised funds accurately and timely, fulfilling its information disclosure obligations [2] Asset Impairment - The supervisory board agreed on the provision for asset impairment, stating that it complied with accounting standards and accurately reflected the company's financial condition and asset value [3] - The decision-making process for the impairment provision was deemed compliant with legal and regulatory requirements [3] Foreign Exchange Derivatives - The supervisory board approved the company's plan to engage in foreign exchange derivative transactions up to $25 million or equivalent in other currencies to mitigate foreign exchange risk [4] - The company established relevant approval and internal control systems for these transactions [4] Use of Additional Funds - The supervisory board approved the use of RMB 237 million of excess raised funds to permanently supplement working capital, enhancing fund utilization efficiency and reducing financial costs [4][5] - This decision aligns with the company's development strategy and benefits all shareholders [5] Governance Changes - The supervisory board agreed to cancel the supervisory board and transfer its powers to the audit committee of the board of directors to improve corporate governance and operational efficiency [5][6] - The legal representative of the company will change from the chairman to the general manager, with corresponding amendments to the company's articles of association [6] - The supervisory board also approved revisions to certain governance documents in line with updated legal and regulatory requirements [6]

Group 1 - The company announced that it will hold its second extraordinary general meeting of shareholders in 2025 on September 12 [1] - The agenda for the meeting includes the proposal to use part of the raised funds to permanently supplement working capital [1]

Group 1 - The core point of the announcement is the decision by Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. to use part of the raised funds to permanently supplement its working capital, amounting to RMB 363.87 million [1][2]. - The decision was made during the third meeting of the fourth supervisory board held on August 4, 2025, with all three supervisors present, ensuring compliance with relevant laws and regulations [1][2]. - The use of the funds is aimed at reducing financial costs, enhancing operational efficiency, and improving profitability, while ensuring that it does not affect the construction of investment projects or the company's daily operations [1][2]. Group 2 - The proposal to use the raised funds requires approval from the company's shareholders' meeting, with a voting result of 3 votes in favor, 0 against, and 0 abstentions [2]. - The decision aligns with the regulations set forth in the "Regulations on the Supervision of Raised Funds by Listed Companies" and other relevant guidelines, ensuring no harm to the interests of the company or minority shareholders [1].

Group 1 - The company held its sixth meeting of the fourth Supervisory Board on June 13, 2025, with all three supervisors present, and the meeting was deemed legally valid [1] - The Supervisory Board approved the use of self-raised funds amounting to 22.3779 million yuan for pre-investment in fundraising projects and payment of part of the issuance costs totaling 4.4262 million yuan, which complies with relevant regulations [1] - The company plans to use no more than 300 million yuan of idle raised funds for cash management, which is expected to enhance fund utilization efficiency and provide better returns for shareholders [2][3] Group 2 - The company intends to temporarily supplement working capital with up to 15 million yuan of idle raised funds, which aligns with regulatory requirements and aims to improve fund efficiency [3] - The Supervisory Board also approved the use of part of the excess raised funds for permanent working capital supplementation, which is expected to lower financial costs and enhance fund utilization [4]

Group 1 - The company held its 19th meeting of the 4th Supervisory Board on May 8, 2025, with all three supervisors present, and the meeting was chaired by Mr. Wang Qiang [1][2] - The Supervisory Board unanimously agreed to use part of the raised funds to permanently supplement working capital, which complies with relevant regulations and does not harm the interests of shareholders, especially minority shareholders [1][2] - The resolution will be submitted to the company's shareholders' meeting for further approval [2]